Is TB-500 Legal in Ohio? How to Access It Through a Licensed Provider

What TB-500 Is and Why Its Regulatory Status Matters

TB-500 is the synthetic, commercially manufactured form of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide first isolated from bovine thymus tissue in the 1960s. Endogenous Thymosin Beta-4 is present in nearly all human and animal cells and plays a documented role in actin sequestration, cell migration, and tissue repair signaling. 1

Because TB-500 is a peptide compound and not a small-molecule drug, it does not fit neatly into the standard FDA new drug application pathway designed for conventional pharmaceuticals. That gap creates real confusion for patients, practitioners, and pharmacies in Ohio who want to use it lawfully.

Why Patients and Clinicians Seek TB-500

Interest in TB-500 among practitioners and patients centers on its proposed role in wound healing, musculoskeletal recovery, and anti-inflammatory signaling. Pre-clinical data from animal models show accelerated healing of cardiac 2, corneal 3, and skeletal muscle tissue after TB-4 administration. A 2010 study in the Journal of Molecular Medicine found that Thymosin Beta-4 reduced infarct size and improved cardiac function in a murine model, pointing to possible cardioprotective mechanisms. 2

Human clinical trial data remain limited. RegenerRx Biopharmaceuticals conducted Phase II trials of the related topical compound RGN-352 (a systemic TB-4 formulation) for acute myocardial infarction. 4 Those trials did not produce Phase III confirmatory data sufficient for FDA approval, which is a key reason TB-500 has no approved drug status today.

The Regulatory Gray Zone Explained

The phrase "regulatory gray zone" has a precise meaning here. TB-500 is not a scheduled controlled substance under the federal Controlled Substances Act, 5 so possessing it is not a criminal drug offense the way possessing Schedule II opioids without a prescription would be. At the same time, it is not an FDA-approved drug, which means manufacturing, marketing, or selling it as a finished human therapeutic without FDA authorization violates the Federal Food, Drug, and Cosmetic Act. 6

The only lawful pathway for a patient to obtain TB-500 for human use is through the 503A compounding pharmacy exemption or, in limited institutional contexts, through a 503B outsourcing facility.

Federal Law: FDA, 503A, and the Bulk Substances Question

How the 503A Exemption Works

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed compounding pharmacies to prepare drug compounds, including peptides, from bulk active pharmaceutical ingredients (APIs) without an approved new drug application, provided specific conditions are met. 6 Those conditions include:

• A valid, patient-specific prescription from a licensed practitioner
• Compounding performed by or under the supervision of a licensed pharmacist
• Use of bulk APIs that meet USP or NF standards, or come from an FDA-registered facility
• The compound is not on the FDA's list of drugs withdrawn from the market for safety reasons
• The compound is not a copy of a commercially available FDA-approved drug

TB-500 does not fall under any of those disqualifying categories as of the date of this article's last review.

The FDA's Bulk Substances List and TB-500

The FDA maintains a list of bulk drug substances it is evaluating for use in 503A compounding. This list was substantially expanded in 2023 as the agency reviewed peptide compounds more systematically. 7

TB-500 (as Thymosin Beta-4) is under evaluation on that list, meaning the FDA has not issued a final determination that it may or may not be used in 503A compounding. Under the agency's current enforcement posture, compounds listed as "under evaluation" may still be compounded by 503A pharmacies while the review is ongoing, unless the FDA issues a negative final determination or an interim guidance specifically withdrawing that permission.

Practitioners should monitor FDA updates closely. A negative final determination on the 503A bulk list would immediately restrict access, even through compounding pharmacies.

503B Outsourcing Facilities

503B outsourcing facilities operate under stricter FDA oversight, including registration with the agency and compliance with current Good Manufacturing Practice standards. 8 They may compound drugs without patient-specific prescriptions for hospital and clinic use. Very few 503B facilities currently compound TB-500, given the regulatory uncertainty, though the option exists if a facility chooses to list it and the FDA does not prohibit it.

Ohio State Law: The Pharmacy Board and Prescribing Authority

Ohio State Board of Pharmacy

Ohio pharmacy law is codified in Ohio Administrative Code (OAC) Chapter 4729 and the Ohio Revised Code (ORC) Chapter 4729. The Ohio State Board of Pharmacy licenses and regulates all pharmacies, including compounding pharmacies, operating within the state. 9 Ohio pharmacies must comply with both state rules and the federal 503A framework described above.

No Ohio-specific statute bans TB-500 by name. Ohio has not placed Thymosin Beta-4 on any state controlled substance analog list, nor has the Ohio Board of Pharmacy issued any advisory specifically prohibiting its compounding or dispensing as of this article's last review date.

This is a key practical point. Because Ohio has not enacted state-level restrictions beyond those imposed federally, a valid prescription from an Ohio-licensed practitioner to a state-licensed 503A compounding pharmacy is, at present, a lawful pathway for TB-500 access.

Who Can Prescribe TB-500 in Ohio

Ohio Medical Practice Act (ORC 4731) authorizes licensed physicians (MDs and DOs) to prescribe any non-controlled compound for any patient for whom they have established a valid prescriber-patient relationship and for whom the prescription serves a legitimate medical purpose. 10 Nurse practitioners (CNPs) and physician assistants (PAs) operating within their Ohio-defined scope of practice and under their respective collaborative or supervisory agreements may also prescribe compounded peptides, subject to their prescriptive authority classifications.

A prescription for TB-500 must include:

• Patient name and date of birth
• Prescriber's name, DEA number (if applicable), and Ohio license number
• Compound name, strength, dosage form (typically injectable solution), quantity, and directions
• Date of issue and authorized refills (if any)

Telehealth Prescribing in Ohio

Ohio Senate Bill 129 (2021) and subsequent telehealth rules aligned Ohio with the federal Ryan Haight Act framework for telehealth prescribing. 11 Because TB-500 is not a controlled substance, the Ryan Haight restrictions on prescribing controlled substances via telehealth do not apply. A licensed Ohio practitioner may prescribe TB-500 through a telehealth visit, provided the practitioner conducts a good-faith medical evaluation and documents a legitimate clinical indication.

The Research Chemical Market: Why It Is Not a Legal Option

A substantial online market sells TB-500 labeled "for research use only" or "not for human use." These products are sold by unregulated vendors who exploit the fact that peptide synthesis itself is not illegal. Purchasing such products and injecting them represents a clear violation of federal law, specifically the prohibition against introducing unapproved new drugs into interstate commerce. 12 The FDA has sent warning letters to multiple peptide research chemical vendors since 2020 for exactly this reason. 13

Beyond legality, quality and safety are genuine concerns with research-grade peptides. These products are not manufactured under pharmaceutical GMP standards. Contamination with bacterial endotoxins, incorrect peptide sequences, and inaccurate concentrations have all been documented in independent third-party testing of research-grade peptides. 14

Patients should not equate the fact that "research peptide" vendors openly list their products online with any form of legal authorization for human use. They are not the same thing.

Clinical Context: What the Evidence Actually Shows

Understanding the legal pathway for TB-500 is easier when the clinical evidence is presented alongside it. Physicians evaluating TB-500 for their patients are weighing pre-clinical promise against a limited human trial database.

Pre-Clinical Evidence

Animal studies establish the mechanistic rationale for TB-500. A 2012 review published in Annals of the New York Academy of Sciences summarized evidence that Thymosin Beta-4 promotes keratinocyte migration, angiogenesis, and stem cell differentiation in multiple tissue types. 1 Subcutaneous and intraperitoneal administration in rodent models produced measurable reductions in inflammatory markers including TNF-alpha and IL-6. 15

A 2010 study using an ischemia-reperfusion cardiac injury model found that systemic Thymosin Beta-4 administration reduced infarct size by approximately 25% compared with saline controls. 2 These are promising animal data, but they cannot be extrapolated directly to human dosing or clinical outcomes without Phase III confirmation.

Human Trial Data

The most rigorous human data come from RegenerRx's RGN-352 program. A Phase II randomized trial (N=73) evaluated intravenous Thymosin Beta-4 in patients with ST-elevation myocardial infarction. Ejection fraction improvement in the treatment arm did not reach statistical significance (P<0.05 threshold was not crossed), though the trial was not powered to detect small differences. 4

Topical RGN-257 (a TB-4 gel) was evaluated in Phase II for neurotrophic corneal injuries and showed statistically significant improvement in corneal healing at 28 days versus vehicle control. 3 This is the most statistically strong human trial data available in the TB-4 literature.

No large-scale Phase III RCT of systemic TB-500 in any musculoskeletal or recovery indication has been completed to date.

What Prescribers Are Documenting as Indications

Practitioners currently prescribing compounded TB-500 within the lawful 503A framework most often document indications such as:

• Chronic tendon or ligament pathology unresponsive to standard physical therapy
• Post-surgical soft-tissue healing support
• Inflammatory musculoskeletal conditions managed alongside other treatments

No FDA-approved labeling supports these uses. Prescribers are exercising off-label judgment, which is lawful, but the clinical decision must be documented with reference to the available evidence and the patient's specific circumstances.

Typical Compounding Specifications and Dosing Seen in Clinical Practice

Compounding pharmacies in Ohio that prepare TB-500 typically provide it as a lyophilized powder in multi-dose vials for reconstitution with bacteriostatic water, or as a pre-mixed injectable solution. Common vial sizes range from 2 mg to 10 mg per vial.

Dosing protocols referenced in the pre-clinical and Phase II literature range from 2 mg to 6 mg administered subcutaneously two to three times per week during an initial loading phase of four to six weeks. 4 Maintenance dosing, where practitioners elect to continue therapy, is typically reduced to 2 mg once per week.

These are not FDA-approved dosing regimens. They reflect extrapolations from animal models and the limited human trial data available. A prescribing physician must determine appropriate dosing based on individual patient assessment, body weight, renal function, and the specific clinical indication.

How to Access TB-500 Legally in Ohio: A Step-by-Step Overview

Getting TB-500 through a lawful channel in Ohio requires several sequential steps, each of which protects both the patient and the prescribing practitioner.

Step 1: Consult a Licensed Ohio Practitioner

Schedule a consultation with an Ohio-licensed MD, DO, NP, or PA who has experience with peptide therapy. The consultation should include a full medical history, review of prior treatments for the relevant condition, and documentation of why TB-500 is being considered. Telehealth consultations with Ohio-licensed providers are permitted and widely available through hormone and peptide-focused practices.

Step 2: Receive a Patient-Specific Prescription

The practitioner issues a written prescription, which must meet the specifications outlined above in the Ohio prescribing authority section. Generic "standing orders" or blanket prescriptions without a named patient are not compliant with 503A requirements.

Step 3: Fill the Prescription at a 503A-Compliant Pharmacy

Choose an Ohio-licensed 503A compounding pharmacy that sources Thymosin Beta-4 API from an FDA-registered supplier and performs internal quality testing (sterility, potency, endotoxin). Ask the pharmacy for a Certificate of Analysis on the API batch. Reputable compounding pharmacies provide this without hesitation. The FDA's guidance on quality standards for compounded sterile preparations is available for reference. 16

Step 4: Administer Under Practitioner Guidance

Self-administration of subcutaneous injections is common for compounded peptides. The prescribing practitioner should provide injection technique training or refer the patient to a nurse educator. Proper storage (typically refrigerated at 2 to 8 degrees Celsius for reconstituted product) and sterile injection technique are non-negotiable safety requirements. 17

Enforcement Posture and Practical Risk Assessment

The FDA's current enforcement priorities for peptide compounds have focused on vendors selling unapproved products directly to consumers without prescriptions, not on 503A pharmacies dispensing patient-specific prescriptions. 13 a negative final determination on the 503A bulk substances list would change this field quickly.

As one HealthRX physician advisor notes: "The window for lawful TB-500 access through compounding is real but narrow. Patients who want it should move through a licensed prescriber and a PCAB-accredited pharmacy now, not through a research chemical website, because the FDA is actively tightening the peptide compounding category."

Practitioners prescribing TB-500 should maintain detailed documentation of the clinical rationale, the informed consent discussion covering the off-label and experimental nature of the treatment, and the compounding pharmacy's quality credentials.

Ohio Residents Outside Major Metro Areas

Patients in rural Ohio counties have the same legal access pathway as those in Columbus, Cleveland, or Cincinnati. Ohio does not restrict telehealth prescribing by geography for non-controlled substances. A telehealth consultation with an Ohio-licensed provider, followed by mail-delivery of the compounded prescription from a licensed Ohio (or out-of-state, federally compliant) compounding pharmacy, is a fully lawful option. The pharmacy must hold an active license in the state to which it ships product; most PCAB-accredited compounding pharmacies maintain multi-state licensing.